Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.58

-1.0%

Nov 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5758)	2/27/2002 9:20:02 AM
From: Ian@SI	Read Replies (1) of 52153

Is there any way of knowing when the data could be available from the German trial now underway? i.e. - How realistic is the expectation of Erbitux approval by next spring? Thanks, Ian ++++++++++ 02/27 08:58 ImClone Asks FDA to Review Results of European Erbitux Tests By Angela Zimm New York, Feb. 27 (Bloomberg) -- ImClone Systems Inc. said it asked U.S. regulators to consider results of U.S. and European trials of its stalled Erbitux cancer drug. ImClone and partner Bristol-Myers Squibb Co. met with the U.S. Food and Drug Administration yesterday to discuss what further steps the agency might require before it will review the Erbitux application, which the agency refused to consider in December. ImClone ``discussed an approach'' in which the FDA would review results of tests already conducted in the U.S. and ongoing trials in Europe, the company said in a faxed statement. ImClone shares rose as high as $23.50 in Instinet trading before the opening of U.S. markets, after closing at $15.52 yesterday.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next